{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.6","value":"76.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"256"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.7","value":"121"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"90.1","value":"154"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"98.6","value":"201"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"102","value":"213"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"title":"Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"128","value":"245"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"110","value":"276"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Cycle 32 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"160","value":"252"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Cycle 40 Day 1"},{"categories":[{"measurements":[{"comment":"Not estimable because there is only 1 participant.","groupId":"OG000","spread":"NA","value":"555"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 48 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"88.8","value":"121"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"}],"units":"Participants"}],"title":"Treatment Discontinuation Visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"256"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG000","title":"Atezolizumab"}],"paramType":"MEAN","populationDescription":"PK analyses was based on PK observations from all randomized participants who received atezolizumab and provided at least one PK sample that was evaluable.","reportingStatus":"POSTED","timeFrame":"Prior to infusion (0 hour) on Day 1 of Cycles 2, 3, 4, 8, 16, and every eighth cycle thereafter, and at treatment discontinuation until data cut-off on 10 September 2018 (up to approximately 38 months) (cycle duration = 21 days)","title":"Minimum Observed Serum Concentration (Cmin) of Atezolizumab","type":"SECONDARY","unitOfMeasure":"micrograms per milliliter (μg/ mL)"}